Evommune pulls in $83m Series A
Evommune, Inc., a private R&D company and innovation engine in chronic inflammation, has secured $83 million in Series A financing.
Evommune, Inc., a private R&D company and innovation engine in chronic inflammation, has secured $83 million in Series A financing.
Copyright PEI Media
Not for publication, email or dissemination